The PILLS Act amends the Internal Revenue Code to create two targeted tax incentives: a production credit (new section 45BB) that pays a percentage of the value a U.S. taxpayer adds when producing approved generic drugs and licensed biosimilars, and an investment credit (new section 48F) that provides 25% of qualified investment in facilities used to produce those products. The production credit includes a base credit (30% or 35% for final drug/biologic production), a domestic content bonus calculated as domestic percentage × 0.20, and a multi‑year phase‑out ending after 2033.
Beyond rates, the bill restricts eligibility (excluding ‘‘foreign entities of concern’’ and components tied to unresolved FDA warning letters), allows elective cash‑out/transferability mechanics under sections 6417/6418, and sets different effective dates for production and investment provisions. For manufacturers, investors, and tax advisers, the measure changes how capital decisions and manufacturing footprints will be evaluated against U.S. tax benefits and regulatory status.
At a Glance
What It Does
Creates a production tax credit equal to a percentage of value added for each eligible generic or biosimilar component produced and sold in the U.S., and an investment tax credit equal to 25% of qualified investment in facilities dedicated to producing those components.
Who It Affects
Domestic generic and biosimilar manufacturers, contract manufacturing organizations, suppliers of inputs and materials, investors building production plants, and tax advisers handling elective payment or credit transfers.
Why It Matters
Targets the economics of on‑shore production through both operating (production) and capital (investment) subsidies, adds a domestic‑content incentive, and uses eligibility rules tied to FDA enforcement and national‑security definitions to steer which facilities and firms can claim benefits.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The PILLS Act creates two linked federal tax incentives to encourage U.S. production of approved generic drugs and licensed biosimilars. The production credit (new section 45BB) pays a percentage of the ‘‘value added’’ the taxpayer creates when it produces an eligible component and sells it to an unrelated buyer; value added equals gross receipts from the sale minus the cost of related eligible components purchased from unrelated parties.
The law sets a base percentage (generally 30%), raises it to 35% for the final production of a drug substance, drug product, or biological product, and allows an additive domestic‑content bonus equal to the domestic content percentage times 0.20—provided the taxpayer documents that domestic content.
Eligibility is narrowly defined. ‘‘Eligible components’’ include approved generics, licensed biosimilars, and most inputs, materials, testing, packaging, and related production activities, but the bill excludes components tied to facilities that currently have unresolved FDA warning letters and bars taxpayers that are ‘‘foreign entities of concern’’ from claiming the credit. The statute defines ‘‘production’’ broadly to capture all manufacturing steps and requires production to occur entirely in the United States to count as ‘‘produced in the United States.’nThe production credit phases down after 2030 (75% in 2031, 50% in 2032, 25% in 2033, and 0% thereafter).
The bill also allows taxpayers to use elective payment and credit‑transfer mechanisms already in sections 6417/6418, enabling non‑taxpaying entities or capital providers to monetize credits in specified circumstances. Separately, the investment credit (new section 48F) gives a 25% credit for qualified property placed in service as part of a ‘‘qualified facility’’ located in the U.S. or U.S. territories, and the statute includes rules for buildings and structural components while excluding office space and coordinating with rehabilitation credits.
That investment credit has a limited window: it applies to property placed in service after December 31, 2026, but will not support property whose construction begins after December 31, 2028.
The Five Things You Need to Know
The production credit bases payouts on value added: gross receipts from the sale of the eligible component minus costs of eligible components purchased from unrelated parties, with a base credit of 30% or 35% for final drug/biologic production.
A domestic‑content bonus increases the base percentage by (domestic content percentage × 0.20) if the taxpayer documents U.S. origin for materials; unrelated suppliers’ certifications are acceptable under the bill’s documentation rules.
The production credit phases out after 2030 using a stepped schedule: 75% of the credit in 2031, 50% in 2032, 25% in 2033, and 0% for sales after 2033.
The investment credit equals 25% of qualified investment in tangible property integral to a qualified facility (including buildings used for production but excluding office space) for property placed in service after Dec 31, 2026; it does not apply to property whose construction begins after Dec 31, 2028.
Taxpayers that are ‘foreign entities of concern’ cannot claim either incentive, and any component partially produced at a facility with an unresolved FDA warning letter is ineligible until the FDA issues a close‑out letter.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the ‘‘Producing Incentives for Long‑term production of Lifesaving Supply of medicine Act’’ or the ‘‘PILLS Act.’' This is purely nominal but signals the legislative intent to target long‑term domestic supply.
Production credit: allowance, scope, and exclusions
Adds section 45BB to subpart D, creating a production credit allowed under section 38 for eligible components that a taxpayer produces in the United States and sells to an unrelated party. The provision mirrors business‑activity rules from section 45X to require production and sale in a trade or business and expressly disqualifies taxpayers designated as foreign entities of concern under the cited NDAA definition.
How the credit is calculated, domestic content bonus, and phase‑out
The credit equals the base credit percentage of the taxpayer’s value added on each eligible component. Value added is defined as gross receipts from the sale minus costs of eligible components bought from unrelated parties. The base percentage is 30%, rises to 35% for final production of a drug substance, drug product, or biological product, and can be increased by a domestic‑content bonus equal to (domestic content percentage × 0.20). The bill requires recordkeeping and permits third‑party certification from unrelated suppliers for domestic content claims. The statute implements a hard phase‑out after 2030 with explicit percentages for 2031–2033 and zero thereafter.
Which products and inputs qualify and operational definitions
Defines ‘‘eligible component’’ broadly to cover approved generic drugs, licensed biosimilars, and an expansive array of inputs and services used in production, but excludes components linked to facilities with unresolved FDA warning letters and property counted under section 48F after enactment. The bill imports FDA definitions for ‘‘approved generic drug,’’ ‘‘drug substance,’’ and ‘‘drug product,’’ defines ‘‘produced in the United States’’ as all production steps taking place in the U.S., and provides a long list of operations that count as production (from synthesis through storage prior to release).
Special rules and regulatory authority; elective payment/transfer mechanics
Applies rules similar to section 45X(d) (procedural and anti‑abuse rules) and directs the Secretary to issue implementing regulations and guidance. Separately, the bill amends sections 6417 and 6418 to allow elective payments (monetization) and transfers of the new production credit under the existing framework that governs similar energy and manufacturing credits, and it adds the credit to the section 38 credit basket so it interacts with general business credit limitations.
Investment credit: 25% credit for qualified facilities and limits
Adds section 48F to create a 25% investment credit for a taxpayer’s qualified investment in qualified property that is part of a qualified facility whose primary purpose is producing eligible components. Qualified property includes tangible depreciable property used as an integral part of the facility, and the provision expressly covers buildings and structural components except where used for offices or unrelated administrative functions. The credit coordinates with the rehabilitation credit, applies progress‑expenditure rules, defines eligible taxpayers (excluding foreign entities of concern), and contains a termination rule: the credit does not apply to property the construction of which begins after December 31, 2028. The bill also sets the effective date for this section to apply to property placed in service after December 31, 2026.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. generic drug and biosimilar manufacturers — receive a per‑component, value‑added operating subsidy that improves margins on domestic production and rewards final‑product manufacturing with a higher base rate.
- Contract manufacturing organizations (CMOs) and facility builders — stand to gain from the 25% investment credit when they place qualified property in service and from increased demand for U.S. manufacturing capacity.
- Domestic suppliers of raw materials, packaging, testing, and secondary services — benefit from the domestic content bonus and an expanded U.S. production ecosystem if manufacturers source inputs locally to increase the credit.
- Investors and private equity funding plant construction — can use the investment credit to improve project economics and, where elective payment rules apply, monetize credits to support financing.
- Hospitals, health systems, and payers (indirect) — may gain more resilient supply chains if the incentives translate into fewer shortages and more reliable availability of generics and biosimilars.
Who Bears the Cost
- U.S. Treasury/IRS — foregoes tax revenue and will face increased administration and enforcement obligations to verify value‑added calculations, domestic content claims, and eligibility tied to FDA status.
- Manufacturers and suppliers subject to new documentation and certification burdens — must track domestic content, segregate production that qualifies as ‘‘produced in the United States,’’ and maintain records supporting third‑party certifications.
- Facilities with unresolved FDA warning letters and entities tied to foreign entities of concern — lose eligibility for credits and may face reduced investment or market value even if remediation would restore compliance.
- Taxpayers and advisers — incur compliance and structuring costs to navigate elective payment options, credit transfers, and interactions with existing credits (e.g., rehabilitation credits), potentially favoring larger firms that can absorb advisory costs.
- Foreign suppliers and offshore producers — may see reduced demand from U.S. buyers seeking to increase domestic content to qualify for the bonus, shifting commercial relationships.
Key Issues
The Core Tension
The central dilemma is whether to prioritize rapid, large‑scale on‑shore manufacturing through generous, time‑limited tax incentives or to guard against fiscal cost and mis‑targeting by demanding tighter, harder‑to‑administer eligibility and verification rules; speeding production with broad credits risks capture and weak oversight, while strict controls reduce the speed and scale of investment the bill seeks to produce.
The bill ties an economically significant subsidy to a value‑added calculation that relies on gross receipts and the cost of purchased eligible components. That choice reduces the need to trace every input upstream but creates opportunities for shifting costs, intercompany pricing adjustments, or structuring purchases through unrelated parties to maximize ‘‘value added.’' The domestic content bonus uses a simple multiplier (domestic percentage × 0.20) but depends on a paper trail and supplier certifications; absent rigorous audit standards and penalties, the bonus risks both over‑claiming and uneven enforcement.
Excluding components tied to unresolved FDA warning letters advances quality incentives but also raises practical questions about the transition path for facilities that are attempting remediation; firms may face a binary cliff where marginal noncompliance eliminates credit eligibility despite substantial corrective actions.
Implementation will hinge on Treasury/IRS regulations. The elective payment and transfer mechanics make credits monetizable, which helps capital‑constrained firms but also enables third‑party intermediaries and tax planning.
The interaction with section 48F (and with other credits like rehabilitation credits) introduces layering concerns: taxpayers must allocate basis carefully to avoid double‑counting and to comply with exclusions. Finally, the phase‑out schedule creates a narrow policy window that could distort timing for long‑lead capital projects—either accelerating investment to capture benefits or deterring projects whose timelines extend beyond the statutory cutoffs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.